Tuberculosis Treatment Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

The tuberculosis treatment market was valued at USD 1.87 Billion in 2025. It is poised to grow at a CAGR of 7.57% during the forecast period of 2026-2035, and reach USD 3.88 Billion by 2035. The market growth is driven by the rising global burden of tuberculosis, the increasing prevalence of drug-resistant TB strains, and growing government and multilateral organization initiatives to accelerate TB elimination.

Key Market Trends and Insights

• Based on disease type, the active tuberculosis segment is expected to be dominant in the forecast period.
• By therapy type, the first-line therapy held nearly 62% market share in the historical period.
• Based on the route of administration, the oral segment held approximately 73% share in the historical period.

Market Size and Forecast

• Market Size (2025): USD 1.87 Billion
• Projected Market Size (2035): USD 3.88 Billion
• CAGR (2026-2035): 7.57%

Tuberculosis Treatment Market Overview

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs (pulmonary TB) but can also involve the kidneys, spine, brain, and other organs. The market is expected to grow at a CAGR of 7.57% over 2026-2035, driven by the persistent disease burden across the 8 major markets. The expanding government-funded treatment programs, the introduction of shorter and more effective drug regimens, and a growing pipeline of novel anti-TB therapies are also expected to accelerate market activity through the forecast period.

Tuberculosis Treatment Market Growth Drivers

Rising Tuberculosis Incidence to Enhance the Market Demand

The increasing incidence of tuberculosis is a key driver supporting growth in the tuberculosis treatment market. In 2024, the Annual Tuberculosis Surveillance Report highlighted that Virginia reported 225 TB cases, reflecting a 9% rise from 2023, alongside an increased case rate of 2.6 per 100,000 individuals. This upward trend, following pandemic-related declines, indicates a resurgence in TB burden, thereby reinforcing the demand for effective treatment solutions and contributing to sustained market growth.

Tuberculosis Treatment Market Trends

Two key trends shaping the market are the advancement of universal regimen therapies.

Advancement of Universal Regimen Therapies is Poised to Accelerate the Market Growth

The growing focus on developing universal, shorter, and more effective tuberculosis treatment regimens is emerging as a significant market trend, driven by the need to address both drug-sensitive and drug-resistant cases with simplified therapies. In November 2023, the TB Alliance initiated a Phase 2 clinical trial evaluating a next-generation compound combined with existing therapies, highlighting innovation in regimen design. This trend is expected to enhance treatment outcomes and support sustained market growth.

Tuberculosis Treatment Market Segmentation

Market Breakup by Disease Type

• Active Tuberculosis
• Latent Tuberculosis

Market Breakup by Therapy Type

• First Line Therapy
• Second Line Therapy

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by Dosage Form

• Tablets
• Capsules
• Injections
• Others

Market Breakup by End User

• Hospitals
• Specialty Clinics
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Market Breakup by Country

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Tuberculosis Treatment Market Share

Oral Expected to Lead the Market Share by Route of Administration

The market is segmented by route of administration into oral, parenteral, and others, reflecting diverse therapeutic delivery approaches. Among these, the oral segment is expected to lead, driven by its convenience and strong patient adherence. This dominance is further supported by advancements in oral drug regimens such as sorfequiline, pretomanid, and linezolid. In November 2025, TB Alliance reported Phase 2 trial results showing that the all-oral SPaL regimen demonstrated greater efficacy than standard therapy and the potential to significantly shorten treatment duration while maintaining a comparable safety profile. This progress reinforces sustained segment growth.

Tuberculosis Treatment Market Analysis by Region

The market is divided into regions such as the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, India emerges as the leading market due to its high tuberculosis burden and strong government initiatives. For instance, in September 2024, India approved the BPaLM regimen under its national program, offering a shorter and more effective treatment for drug-resistant TB, thereby strengthening treatment outcomes and accelerating progress toward disease elimination. Collectively, these advancements are anticipated to drive market expansion and enhance the effectiveness of tuberculosis treatment globally.

Leading Players in the Tuberculosis Treatment Market

The key features of the market report comprise patent analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:

Johnson & Johnson Innovation Inc.

Johnson & Johnson Innovation Inc. contributes to tuberculosis control by combining awareness efforts with improved treatment access. The company backs initiatives like MTV Nishedh in India to promote early diagnosis and reduce social stigma. It also facilitates broader availability of bedaquiline for multidrug-resistant TB while partnering globally to enhance healthcare infrastructure and treatment outreach.

Pfizer Inc.

Pfizer Inc. supports tuberculosis management through Wyeth Pharmaceuticals LLC by offering Trecator® (ethionamide tablets, USP). This oral medication is used in treating active and drug-resistant TB cases as part of combination therapies. Its use helps improve clinical outcomes, reflecting Pfizer’s role in combating antimicrobial resistance and strengthening therapeutic options in tuberculosis care.

Sanofi SA

Sanofi SA addresses tuberculosis through targeted access programs and public health support. Its TB FREE initiative in South Africa emphasizes adherence to treatment using rifampicin-based therapies and DOTS protocols. By focusing on structured care delivery, the company enhances patient outcomes and reinforces its position in improving access to tuberculosis treatments in affected regions.

Eli Lilly and Company

Eli Lilly and Company advances tuberculosis treatment through ongoing investment in research and innovation. By extending funding to the Infectious Disease Research Institute, it supports the development of new therapies for TB and multidrug-resistant strains. The company also shares scientific resources, including compound libraries and expertise, fostering collaboration in the discovery of more effective treatments.

Other key players in the market are AstraZeneca Plc, Viatris Inc. (Mylan N.V.), Teva Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries Ltd., Novartis AG, and Hikma Pharmaceuticals PLC.

Key Questions Answered in the Tuberculosis Treatment Market Report

• What was the tuberculosis treatment market value in 2025?
• What is the tuberculosis treatment market forecast outlook for 2026-2035?
• What major factors aid the demand for the tuberculosis treatment market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major tuberculosis treatment market trends?
• Which disease type is expected to dominate the market segment?
• Which therapy type is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which dosage form segment is expected to record the fastest growth?
• Which end user segment is anticipated to hold the largest market share?
• Which distribution channel is likely to dominate the market segment?
• Who are the key players in the tuberculosis treatment market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
• What country among the 8MM markets is expected to dominate tuberculosis treatment market?